Kullanım Kılavuzu
Neden sadece 3 sonuç görüntüleyebiliyorum?
Sadece üye olan kurumların ağından bağlandığınız da tüm sonuçları görüntüleyebilirsiniz. Üye olmayan kurumlar için kurum yetkililerinin başvurması durumunda 1 aylık ücretsiz deneme sürümü açmaktayız.
Benim olmayan çok sonuç geliyor?
Birçok kaynakça da atıflar "Soyad, İ" olarak gösterildiği için özellikle Soyad ve isminin baş harfi aynı olan akademisyenlerin atıfları zaman zaman karışabilmektedir. Bu sorun tüm dünyadaki atıf dizinlerinin sıkça karşılaştığı bir sorundur.
Sadece ilgili makaleme yapılan atıfları nasıl görebilirim?
Makalenizin ismini arattıktan sonra detaylar kısmına bastığınız anda seçtiğiniz makaleye yapılan atıfları görebilirsiniz.
 Görüntüleme 6
 İndirme 1
Çocuklarda Sugammadeks ve Neostigmin Kullanımının Ekstübasyon Süreleri Açısından Karşılaştırılması
2016
Dergi:  
Haseki Tıp Bülteni
Yazar:  
Özet:

Aim: Sugammadex is a cyclodextrin compound which provides complete recovery of residual neuromuscular blockade. In this study, we compared sugammadex and neostigmine in terms of time to achieve a train-of-four (TOF) ratio of 0.9 and extubation time (TE). Methods: Thirty-seven patients, without lung disease and neuromuscular disease undergoing lower urinary tract surgery and inguinal hernia, were included in the study. Noninvasive arterial pressure, heart rate, pulse oximetry, and TOF-watch SX values were monitored during the surgery and, these parameters were recorded. After the surgery was completed, the patients were randomized into two groups: patients received either group neostigmine (group N) 0.05 mcg/kg and group sugammadex (group S) 2 mg/kg at reappearance of TOF ratio T2. Time to recovery to the TOF ratio of 0.9 (T0.9) and TE were compared between sugammadex and neostigmine. Results: TE was found to be statistically longer in group N (6.06±2.47 minute) than in group S (4.30±2.48 minute) (p<0.041). Conclusion: We observed that sugammadex was more rapidly and effectively reversed the neuromuscular blockade compared to neostigmine. There were no serious adverse effects and significant hemodynamic changes in any measurement time. However, there is a limited number of studies on the safety and side effects of sugammadex in pediatric patients and additional data are needed to establish the safety in clinical practice.

Anahtar Kelimeler:

Comparison of the use of Sugammadeks and Neostigmin in children in terms of exposure times
2016
Yazar:  
Özet:

Sugammadex is a cyclodextrin compound which provides complete recovery of residual neuromuscular blockade. In this study, we compared sugammadex and neostigmine in terms of time to a train-of-four (TOF) ratio of 0.9 and extubation time (TE). Methods: Thirty-seven patients, without lung disease and neuromuscular disease undergoing lower urinary tract surgery and inguinal hernia, were included in the study. Noninvasive arterial pressure, heart rate, pulse oximetry, and TOF-watch SX values were monitored during the surgery and, these parameters were recorded. After the surgery was completed, the patients were randomized into two groups: patients received either group neostigmine (Group N) 0.05 mcg/kg and group sugammadex (Group S) 2 mg/kg at reappearance of TOF ratio T2. Time to recovery to the TOF ratio of 0.9 (T0.9) and TE were compared between sugammadex and neostigmine. Results: TE was found to be statistically longer in group N (6.06±2.47 minutes) than in group S (4.30±2.48 minutes) (p<0.041). Conclusion: We observed that sugammadex was more rapidly and effectively reversed the neuromuscular blockade compared to neostigmine. There were no serious adverse effects and significant hemodynamic changes in any measurement time. However, there is a limited number of studies on the safety and side effects of sugammadex in pediatric patients and additional data are needed to establish the safety in clinical practice.

Atıf Yapanlar
Bilgi: Bu yayına herhangi bir atıf yapılmamıştır.
Benzer Makaleler












Haseki Tıp Bülteni

Alan :   Sağlık Bilimleri

Dergi Türü :   Uluslararası

Metrikler
Makale : 847
Atıf : 376
Haseki Tıp Bülteni